The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
MooreM.J.GoldsteinD.HammJ.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol.2007; 25(15): 1960–1966.
2.
FeliuJ.BorregaP.LeonA.Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemother Pharmacol.2011; 67(1): 215–221.
3.
MilellaM.VaccaroV.SperdutiI.Phase II study of erlotinib (E) combined with fixed dose-rate gemcitabine (FDR-Gem) as first-line treatment for advanced adenocarcinoma of the pancreas (PDAC). J Clin Oncol.2010; 28(suppl): abstract e14565.
4.
Munoz-LlarenaA.ManeJ.Lopez-VivancoG.Gemcitabine (G) fixed dose-rate infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC). J Clin Oncol.2011; 29(suppl 4): abstract 304.
5.
ChunS.LeeM.JeonE.Comparison of the efficacy of gemcitabine with capecitabine and gemcitabine with erlotinib combination chemotherapy in recurrent or advanced pancreatic cancer as first-line treatment: single-center experience. J Clin Oncol.2011; 29(suppl 4): abstract 329.
6.
BaoP.Q.RamanathanR.K.KrasinkasA.Phase II trial of adjuvant gemcitabine and erlotinib for resected pancreatic cancer. Ann Surg Oncol.2011; 18(4): 1122–1129.
7.
NCCN Clinical Practice Guidelines in Oncology for Pancreatic Adenocarcinoma. V.1.2012. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed October 3, 2011.
8.
TemperoM.PlunkettW.Ruiz Van HaperenV.Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol.2003; 21(18): 3402–3408.
9.
NCCN Clinical Practice Guidelines in Oncology for Antiemesis. V.1.2012. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed August 20, 2011.
10.
Multinational Association of Supportive Care in Cancer antiemetic guidelines. March 2011. Multinational Association of Supportive Care in Cancer Web site. www.mascc.org. Accessed August 20, 2011.
11.
NCCN Clinical Practice Guidelines in Oncology for Myeloid Growth Factors. V.1.2011. National Comprehensive Cancer Network Web site. www.nccn.org. Accessed August 20, 2011.
12.
KintzelP.E.DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
13.
DelalogeS.LlombartA.Di PalmaM.Gemcitabine in patients with solid tumors and renal impairment. Am J Clin Oncol.2004; 27(3): 289–293.
